| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10011452 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
| TVIS10011453 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
| TVIS10021160 | HBV | ENSG00000117601.15 | protein_coding | SERPINC1 | No | No | 462 | P01008 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | SERPINC1 |
|---|---|
| DrugBank ID | DB00569 |
| Drug Name | Fondaparinux |
| Target ID | BE0000280 |
| UniProt ID | P01008 |
| Regulation Type | potentiator |
| PubMed IDs | 12383040; 12501872; 15317404; 12383039 |
| Citations | Paolucci F, Clavies MC, Donat F, Necciari J: Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet. 2002;41 Suppl 2:11-8.@@Cheng JW: Fondaparinux: a new antithrombotic agent. Clin Ther. 2002 Nov;24(11):1757-69; discussion 1719.@@Dager WE, Andersen J, Nutescu E: Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy. 2004 Jul;24(7 Pt 2):88S-94S.@@Donat F, Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R: The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41 Suppl 2:1-9. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O |
| Pathways | Fondaparinux Action Pathway |
| PharmGKB | PA164746297 |
| ChEMBL | CHEMBL1201202 |
